RTX-010 / Repeat Therapeutics - LARVOL DELTA

A study to assess safety, tolerability, and pharmacokinetics of RTX-010/101/111 in healthy adults. Part 1A and Part B healthy participants only (ANZCTR) - P1 | N=104 | Recruiting | Sponsor: Repeat Therapeutics Pty Ltd | Initiation date: Nov 2025

First-in-human • Trial initiation date • Amyotrophic Lateral Sclerosis • CNS Disorders

A study to assess safety, tolerability and pharmacokinetics of RTX-010/101/111 for participants with C9orf72-mediated Amyotrophic Lateral Sclerosis (ALS). Part 1C adults with C9orf72-mediated ALS only. (ANZCTR) - P1 | N=16 | Not yet recruiting | Sponsor: Repeat Therapeutics Pty Ltd

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders